Back to Feed
总结
诺和诺德在美国推出Wegovy减重药的口服版本，把部分治疗方案从以往每周注射拓展为每日服用片剂，起始剂量已在药房渠道上架。报道指这是首个在美上市、用于肥胖治疗的GLP-1口服药，旨在以更便利的给药方式扩大可及性。市场与媒体重点关注其定价、保险覆盖和供货能力，以及对2026年减重药竞争格局（与礼来等厂商）和价格变化的潜在影响。
正文
Novo Nordisk debuts Wegovy weight-loss pill in the U.S. CBS News Starter dose of Wegovy now available as a daily pill instead of weekly injection CNN Novo Nordisk's Wegovy Pill Hits Pharmacies. It's the Latest Move in the Weight-Loss Showdown. Barron's First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC What to watch for in weight loss drugs in 2026: Price changes, GLP-1 pills and more NBC News
发布时间：